ADMA Biologics Inc (ADMA)vsAlnylam Pharmaceuticals Inc (ALNY)
ADMA
ADMA Biologics Inc
$9.63
-15.00%
HEALTHCARE · Cap: $2.29B
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 628% more annual revenue ($3.71B vs $510.17M). ADMA leads profitability with a 28.8% profit margin vs 8.5%. ADMA trades at a lower P/E of 16.1x. ADMA earns a higher WallStSmart Score of 56/100 (C).
ADMA
Buy56
out of 100
Grade: C
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-299.0%
Fair Value
$4.08
Current Price
$9.63
$5.55 premium
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 36 in profit
Strong operational efficiency at 45.1%
Safe zone — low bankruptcy risk
Keeps 29 of every $100 in revenue as profit
Attractively priced relative to earnings
18.4% revenue growth
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
Earnings declined 52.8%
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.8% and operating margin at 45.1%. Revenue growth of 18.4% demonstrates continued momentum.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ADMA
The primary concerns for ADMA are EPS Growth.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
ADMA profiles as a growth stock while ALNY is a hypergrowth play — different risk/reward profiles.
ADMA carries more volatility with a beta of 0.59 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ADMA scores higher overall (56/100 vs 49/100), backed by strong 28.8% margins and 18.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?